Patents Assigned to National Institutes for Food and Drug Control
  • Patent number: 11866459
    Abstract: The present invention relates to a cocrystal of progesterone, which is formed by the active ingredient progesterone and a cocrystal former which is selected from isophthalic acid, 4-formylbenzeneboronic acid and 3-nitrophthalic acid. The present invention also relates to the method for preparing the cocrystal of progesterone and use thereof for increasing the thickness of endometrium, improving progesterone's solubility or increasing progesterone's permeation rate.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: January 9, 2024
    Inventors: Lan He, Jing Xiong, Xiangxiang Wu, Xin Zhu, Zhonglin Lu, Yan Shi, Na Zhang, Yang Liu
  • Publication number: 20230260773
    Abstract: The present disclosure provides a method for constructing a correlation model between relative bioavailability and bioaccessibility of cadmium in earthworm, belonging to the technical field of cadmium detection in earthworms. The method includes the following steps: determination of relative bioavailability of cadmium in earthworms, determination of bioaccessibility of cadmium in the earthworm based on an in vitro physiologically-based extraction test (PBET) method, and construction of a correlation model between the relative bioavailability and the bioaccessibility of cadmium in the earthworm. The method enables to directly put the bioaccessibility obtained by the in vitro method into a regression equation to obtain the bioavailability of cadmium in subsequent studies.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 17, 2023
    Applicants: National Institutes for Food and Drug Control, Wang Jing Hospital of CACMS (Orthopedics Research Institute of CACMS), Tongliao Market Inspection and Testing Center
    Inventors: Shuangcheng Ma, Tiantian Zuo, Jia Zhu, Qinghui Song, Wanqiang Zhang, Jishuang Wang, Haiyan Wang, Lei Sun, Hongyu Jin, Qi Wang, Jianbo Yang, Dejuan Kong, Shuai Kang, Jiandong Yu
  • Publication number: 20230087361
    Abstract: A dianthrone compound may be used in preparation of a medicament for prevention and/or treatment of myocardial ischemic diseases and related diseases thereof. The dianthrone compound includes trans-emodin dianthrone and/or cis-emodin dianthrone.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 23, 2023
    Applicants: National Institutes for Food and Drug Control, Institute of Materia Medica Chinese Academy of Medical Sciences
    Inventors: Shuangcheng MA, Hua SUN, Feng WEI, Jianbo YANG, Ting OUYANG, Qi WANG, Zihan CHEN, Ying WANG, Yunfei SONG, Zhiwei CHEN, Huiyu GAO, Xueting WANG